First quarter 2024 report

30. Apr 2024 | 3 min read

Moss, 30 April 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the first quarter 2024.



  • Record sales of NOK 38.5 million in 1Q24, up 22% vs 1Q23 (19% organic growth)
  • EBITDA of NOK 4.8 million in 1Q24 versus NOK -0.5 million in 1Q23
  • Gross margin of 53% positively influenced by favourable product mix and finalisation of integration with Getica AB, which was acquired in July 2023
  • Sales of fCAL® turbo increased 44% in 1Q24 compared to 1Q23
  • Continued solid development for third party sales which increased 31% in 1Q24 compared to 1Q23
  • New KDIGO Guidelines issued during 1Q24 recommends increased use of Cystatin C
  • Significant advancements achieved in the technical development and production upscaling of the NT-proBNP assay

GDASA interim report 1Q 2024

GDASA Q1 24 presentation



The company will present the results today at 09.00 am, followed by a Q&A session.

Join the webcast and submit questions via the following link:

The webcast will be available on the company website after the presentation.


IR contact:

Njaal Kind, CEO

+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. This stock exchange announcement was published by Ole Sørlie, Business Controller at Gentian Diagnostics ASA, on 30 April 2024 at 08:00 CET.


About Gentian

Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit

You may also read